STOCK TITAN
  1. Home
  2. News
  3. DTCFF

DEFENCE THERAPEUTICS A - DTCFF STOCK NEWS

Welcome to our dedicated page for DEFENCE THERAPEUTICS A news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on DEFENCE THERAPEUTICS A stock.

Defence Therapeutics Inc. (symbol: DTCFF) is a Canadian biopharmaceutical company specializing in immune-oncology therapeutics and drug delivery technologies. The company recently announced the successful development of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an anti-PD-1 immune-checkpoint inhibitor. Defence's unique approach involves the use of reprogrammed mesenchymal stromal cells and AccuTOX® to induce potent antigen presentation for enhanced immune response. The ARM-002TM vaccine is highly versatile and adaptable, being tested on

News

Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics

Rhea-AI Summary
Defence Therapeutics continues to bring innovative strategies targeting immune-oncology indications. Their Accum® technology enhances bio-drug efficacy against cancer. ADCs improved potency by 20-100 folds. Partnership with Orano for next-gen ADC therapies. Dual acting vaccine shows 70-100% survival rate. ARM vaccine demonstrates high cure rates in lymphoma and melanoma. AccuTOXTM program halts pre-established cancers and activates immune response. IND filing expected in Q4 2023. Global oncology market valued at USD 208B in 2022, projected to reach USD 628B by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Defence's Innovative Therapeutics Featured on Viewpoint with Dennis Quaid

Rhea-AI Summary
Defence Therapeutics to be featured on Viewpoint, a national educational TV show, highlighting breakthroughs in biotechnology and therapeutics innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
none
-
News

Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano

Rhea-AI Summary
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) successfully reached the first milestone in the Collaboration Agreement with Orano Support SAS to develop next-generation radio-immunoconjugates using Defence's intracellular targeting technology. The milestone involves synthesizing the AccuTOXTM peptide containing the DOTA chelator and the Azide moiety. The company aims to develop novel radio-based therapies with higher specificity and selectivity, ensuring increased therapeutic efficacy with lower adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.49%
Tags
none
News

RETRANSMISSION: Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
none
-
News

Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Defence Patent Portfolio at the Forefront of Success

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Defence's Proprietary Accum(TM) Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application Published

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Defence Manufacturing of AccuTox(TM) CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of Hope

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Defence Begins Testing Its Arm Vaccine Against Pancreatic Cancer

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
none

FAQ

What is the current stock price of DEFENCE THERAPEUTICS A (DTCFF)?

The current stock price of DEFENCE THERAPEUTICS A (DTCFF) is $0.4093 as of November 21, 2024.

What is the market cap of DEFENCE THERAPEUTICS A (DTCFF)?

The market cap of DEFENCE THERAPEUTICS A (DTCFF) is approximately 19.1M.

Stock DTCFF logo
DEFENCE THERAPEUTICS A

OTC:DTCFF

DTCFF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

DTCFF Stock Data

19.09M
44.62M
4.58%
Biotechnology
Healthcare
Link
United States of America
Vancouver